ICER FINDINGS LIKELY TO BOOST UPTAKE OF XTANDI AND ERLEADA IN NON-METASTATIC DISEASE AS PAYERS LOOK TO MORE AGGRESSIVELY MANAGE THE CLASS Midwest Comparative Effectiveness Public Advisory Council (CEPAC) Public Hearing on Prostate Cancer Drugs Reviewed: Zytiga (Janssen), Erleada (Janssen), and Xtandi (Pfizer/Astellas)

Text Registration

ICER FINDINGS LIKELY TO BOOST UPTAKE OF XTANDI AND ERLEADA IN NON-METASTATIC DISEASE AS PAYERS LOOK TO MORE AGGRESSIVELY MANAGE THE CLASS Midwest Comparative Effectiveness Public Advisory Council (CEPAC) Public Hearing on Prostate Cancer Drugs Reviewed: Zytiga (Janssen), Erleada (Janssen), and Xtandi (Pfizer/Astellas)

Status

Published

on 11 Sept 2019

Year of Creation

2018

IPD Analytics LLC

Registration Number

TX0008812827

on 11 Sept 2019

The U.S. Copyright record (Registration Number: TX0008812827) dated 11 Sept 2019, pertains to an electronic file (eService) titled "ICER FINDINGS LIKELY TO BOOST UPTAKE OF XTANDI AND ERLEADA IN NON-METASTATIC DISEASE AS PAYERS LOOK TO MORE AGGRESSIVELY MANAGE THE CLASS Midwest Comparative Effectiveness Public Advisory Council (CEPAC) Public Hearing on Prostate Cancer Drugs Reviewed: Zytiga (Janssen), Erleada (Janssen), and Xtandi (Pfizer/Astellas)" created in 2018. The copyright holder is IPD Analytics LLC, known for their creative contributions in text registration. For any inquiries concerning this copyrighted material, kindly reach out to IPD Analytics LLC.

IPD Analytics LLC

Application Details

Registration Number

TX0008812827

Registration Date

9/11/2019

Year of Creation

2018

Agency Marc Code

DLC-CO

Record Status

New

Corporate Author

IPD Analytics LLC

Physical Description

Electronic file (eService)

First Publication Nation

United States

Corporate Authors

IPD Analytics LLC

Statements

Application Title Statement: ICER FINDINGS LIKELY TO BOOST UPTAKE OF XTANDI AND ERLEADA IN NON-METASTATIC DISEASE AS PAYERS LOOK TO MORE AGGRESSIVELY MANAGE THE CLASS Midwest Comparative Effectiveness Public Advisory Council (CEPAC) Public Hearing on Prostate Cancer Drugs Reviewed: Zytiga (Janssen), Erleada (Janssen), and Xtandi (Pfizer/Astellas)

Author Statement: IPD Analytics LLC employer for hire Domicile: United States Citizenship: United States Authorship: text

Statements

Author Statement: IPD Analytics LLC employer for hire Domicile: United States Citizenship: United States Authorship: text

Get your copyright registered todayThousands have copyrighted their assets.
What are you waiting for?

Show terms & conditions

Disclaimer: The information contained in this website is provided for informational purposes only, and should not be construed as legal advice. Although LegalForce RAPC Worldwide P.C., dba Trademarkia P.C., is a law firm (the “Firm”), your use of this website does not establish an attorney-client relationship with the Firm. Such a relationship can only be established after the Firm decides that it is willing and able to accept the engagement after a conflict check and after a written retainer agreement is agreed upon between you and the Firm. Your use of this website is also subject to our Terms of Use and Privacy Policy. ** The entry level subscription is a bundled price which requires a minimum of two billing cycles, or 6 months.